Skip to content

Pharmaceuticals in Brazil Customer Challenges and Pains Analysis

Challenges and Pains faced by Customers

Customers within the Brazilian pharmaceutical value chain, encompassing individual consumers, retail pharmacies, hospitals and clinics, and the public health system (SUS), encounter a range of challenges and pains throughout the process of accessing and utilizing pharmaceutical products. These difficulties stem from structural issues within the value chain, the regulatory environment, market dynamics, and logistical complexities.

Individual consumers, as the end-users, face pains related to the accessibility and affordability of medicines. The high cost of medicines is a significant concern, influenced by factors such as reliance on imported raw materials and the costs associated with research and development and regulatory compliance. Access can also be challenging due to logistical hurdles in Brazil's vast territory, potentially leading to limited availability in remote or underserved areas. Furthermore, the risk of counterfeit or substandard medicines entering the supply chain poses a serious threat to consumer safety and trust. Individual consumers also express a strong preference for increased domestic production of medicines and inputs, suggesting a pain point related to perceived dependence on foreign supply.

Retail pharmacies, acting as a crucial interface with the public, experience challenges primarily related to intense market competition and operational burdens. The retail sector is marked by fierce competition, particularly among large pharmacy chains, which can put significant pressure on the margins of independent pharmacies and potentially reduce consumer choice in certain locations as consolidation occurs. Retailers also face the complex task of managing inventory efficiently and ensuring a consistent supply of a wide range of products from distributors and manufacturers. Adhering to the complex and evolving regulatory requirements from ANVISA for pharmacy operations and dispensing practices adds another layer of operational pain.

Hospitals and clinics, as institutional customers, require a reliable and consistent supply of a broad spectrum of pharmaceutical products, including specialized and high-cost medications. A key pain point for these institutions is ensuring the availability of these critical supplies, which can be affected by logistical complexities and potential vulnerabilities in the supply chain, particularly for imported items. They also need specialized distribution services capable of handling specific storage and delivery requirements, such as cold chain management for certain products.

The Public Health System (SUS), a major institutional customer, faces the significant challenge of ensuring broad and equitable access to essential and strategic medicines for the entire population, often at no direct cost to the patient. The primary pains for the SUS involve navigating complex and often bureaucratic public procurement processes (tenders) and managing budgetary constraints against the high and constant demand for medicines. Ensuring the timely and safe delivery of large volumes of medications to public health facilities across the country, particularly in remote regions, presents substantial logistical challenges.

These challenges and pains across different customer segments are interconnected and often originate from upstream issues in the value chain.

Prioritized Table of Challenges and Pains

Based on the frequency and emphasis in the provided reports, the main challenges and pains faced by customers in the Brazilian pharmaceutical value chain can be prioritized as follows:

Priority Challenge/Pain Affected Customer Segments
1 Supply Chain Vulnerability due to High Import Dependence (APIs) All (Consumers, Retail, Hospitals, SUS - indirectly through availability/cost)
2 High Cost and Affordability of Medicines Individual Consumers, SUS
3 Logistical and Distribution Challenges (Cost, complexity, reach) Retail, Hospitals, SUS (impacting Consumers' access)
4 Complex and Burdensome Regulatory Environment (ANVISA) Retail, Hospitals, SUS (operational burden, impacting access/cost)
5 Intense Retail Competition and Market Consolidation Retail Pharmacies (especially independents), Individual Consumers (choice)
6 Risk of Counterfeit and Illicit Trade Individual Consumers, All (safety/trust)
7 Ensuring Consistent and Reliable Supply Retail, Hospitals, SUS
8 Navigating Public Procurement Processes and Budget Constraints SUS
9 Limited Domestic R&D and Reliance on Imported Innovative Drugs All (access to new therapies, potentially cost)

Correlation with Value Chain

The challenges and pains faced by customers in the Brazilian pharmaceutical market are directly correlated with specific steps and dynamics within the value chain:

  • Input Production (Farmoquímica): The most significant pain correlated here is the Supply Chain Vulnerability due to High Import Dependence (APIs). Since approximately 90% of Active Pharmaceutical Ingredients are imported, customers downstream face risks of supply disruptions, price fluctuations influenced by international markets and currency exchange rates. This directly impacts the Ensuring Consistent and Reliable Supply for manufacturers, distributors, and ultimately, retail and healthcare providers, translating into potential availability issues and contributing to the High Cost and Affordability of Medicines for consumers and the SUS.
  • Pharmaceutical Production: Challenges in this stage, such as the High Cost and Risk of Research & Development, contribute to the reliance on imported innovative drugs and can influence the final price of medicines, impacting High Cost and Affordability. While Brazilian companies excel in generics and similars, the Limited Domestic R&D for novel drugs means customers remain dependent on international sources for new therapies. The need to comply with Complex and Burdensome Regulatory Environment (ANVISA) during production adds operational costs and can delay market entry for new or updated products, indirectly affecting availability and cost for all customer types.
  • Distribution: This step is directly linked to the Logistical and Distribution Challenges. Brazil's vast territory and infrastructure issues make the transportation of medicines costly and complex, especially for products requiring controlled conditions (like cold chain). This directly impacts the ability of distributors to ensure Ensuring Consistent and Reliable Supply to retail pharmacies, hospitals, and public health posts across all regions, leading to potential Access and Availability pains for individual consumers, particularly in remote areas. The Complex and Burdensome Regulatory Environment also affects distribution (e.g., RDC 430/2020 on temperature control), adding operational complexity and cost.
  • Retail & Commercialization: Pains at this final stage are felt directly by individual consumers and impact the viability of retail businesses. Intense Retail Competition and Market Consolidation pose a significant challenge for independent pharmacies, potentially limiting consumer choice. Retailers directly manage the High Cost and Affordability of Medicines as they are the point of sale, dealing with consumer price sensitivity and regulatory pricing controls. They are also on the front line for ensuring Quality and Safety and mitigating the Risk of Counterfeit and Illicit Trade through proper dispensing and adherence to regulations. The operational burden of the Complex and Burdensome Regulatory Environment (ANVISA rules for pharmacies) is also a direct pain point for retailers.
  • Business-to-Government (B2G) / Public Health System (SUS): Although the SUS is a customer type, its challenges correlate strongly with various value chain steps. The ability of the SUS to ensure broad Access and Availability is dependent on efficient procurement from manufacturers and distributors, which can be hindered by the Logistical and Distribution Challenges and complexities in the supply chain stemming from High Import Dependence. The High Cost and Affordability of Medicines directly impacts the SUS budget, making Navigating Public Procurement Processes and Budget Constraints a significant pain. The Complex and Burdensome Regulatory Environment also applies to the quality and registration of products procured by the SUS.

In summary, challenges originating from upstream stages like Input Production (import dependence) and Pharmaceutical Production (R&D costs, regulation) propagate downstream, influencing costs, availability, and operational complexity for distributors, retailers, and healthcare providers, ultimately impacting the cost and access experienced by individual consumers and the public health system. Logistical challenges inherent in the Distribution stage directly translate into pains related to access and reliable supply for all downstream customers. Market dynamics and regulatory burdens within the Retail stage create competitive pressures and operational pains that can affect consumer choice and the cost of medicines.

References

  • Abradilan. Dez maiores farmacêuticas do Brasil detêm 48,6% das vendas.
  • Abradilan. Crescimento das grandes redes de farmácias.
  • Abradilan. Setor farmacêutico cresce 12,7% em 2024, mas reajuste autorizado gera dúvidas e impacto no bolso do consumidor.
  • Agência Gov. Nova Indústria Brasil contribuirá para fortalecer produção de medicamentos.
  • Anvisa. Anvisa divulga dados do anuário sobre a indústria farmacêutica no Brasil.
  • Anvisa. Aprovado novo marco regulatório de BPF.
  • BNDES. Cadeia farmacêutica no Brasil: avaliação preliminar e perspectivas.
  • CDPI Pharma. O tamanho da indústria farmacêutica nacional.
  • CDPI Pharma. O investimento da indústria farmacêutica em pesquisa e desenvolvimento.
  • CFF Admin. Por que o Brasil não avança na pesquisa e desenvolvimento de ativos farmacêuticos?.
  • CNN Brasil. Brasil importa 90% da matéria-prima para a produção de medicamentos.
  • Dr. Fisiologia. Indústria farmacêutica brasileira e suas tendências (2025).
  • Febrafar. Varejo farmacêutico: veja destaques de 2024 e expectativas para 2025.
  • FIA. Indústria farmacêutica: características, setores e mercado de trabalho.
  • Grupo FarmaBrasil. Pesquisa, desenvolvimento e inovação no Setor Farmacêutico: o Brasil no cenário internacional.
  • Grupo Palmed. Distribuidoras de Medicamentos.
  • ICTQ. 14 atualizações regulatórias para a Indústria Farmacêutica em 2018.
  • ICTQ. Os modelos de negócios farmacêuticos.
  • ICTQ. Anvisa - Confira as principais atualizações regulatórias que ocorreram nos últimos seis meses.
  • InvesteSP. Setor farmacêutico é o que mais investe em pesquisa e desenvolvimento.
  • MOOC Fiocruz. Indústria Farmacêutica no Brasil: um breve panorama.
  • MOOC Fiocruz. Estágios da produção de medicamentos.
  • Medicina SA. 90% dos brasileiros preferem a produção de medicamentos e insumos no país.
  • Medicina SA. Três grandes grupos de redes de farmácias concentram 40% do mercado no Brasil.
  • Medicina SA. Varejo farmacêutico cresce 11% e movimenta R$ 158,4 bilhões em 2024.
  • Natcofarma. Varejo farmacêutico: Confira as principais tendências.
  • Omni Hospitalar. Como funciona o processo de distribuição de medicamentos?.
  • Panorama Farmacêutico. Dez maiores laboratórios do Brasil têm 55% do mercado.
  • Quais são as maiores empresas farmacêuticas do Brasil e do mundo?.
  • Qualifica. Legislação Sanitária para Indústria Farmacêutica: o que mudou?.
  • Sebrae. Como montar uma distribuidora de medicamentos.
  • Sotequi Vedações Industriais. Segmento farmaceutica.
  • Sulmedic. Distribuição de Medicamentos Hospitalares.
  • Os Tipos de Empresas Farmacêuticas :: Gestão Farmacêutica.
  • VEJA. 90% dos brasileiros dizem que produção nacional de remédios deve aumentar.
  • VEJA. Varejo farmacêutico cresce 11% e movimenta R$ 158,4 bi em 2024.
  • Vernalha Pereira. Novas regras da Anvisa e o seu impacto no registro de medicamentos para a indústria farmacêutica.